Back to Search
Start Over
Single-agent expansion cohort of lenvatinib (LEN) and combination dose-finding cohort of LEN + etoposide (ETP) + ifosfamide (IFM) in patients (pts) aged 2 to ≤25 years with relapsed/refractory osteosarcoma (OS)
- Source :
- Journal of Clinical Oncology. 36:11527-11527
- Publication Year :
- 2018
- Publisher :
- American Society of Clinical Oncology (ASCO), 2018.
-
Abstract
- 11527Background: LEN is a multikinase inhibitor of VEGFR1-3, FGFR1-4, PDGFRα, KIT, and RET. In human pediatric OS xenograft models, LEN enhanced the antitumor activity of IFM + ETP. In a phase (Ph)...
- Subjects :
- 0301 basic medicine
Oncology
Cancer Research
medicine.medical_specialty
Ifosfamide
business.industry
medicine.disease
03 medical and health sciences
chemistry.chemical_compound
Dose finding
030104 developmental biology
0302 clinical medicine
chemistry
030220 oncology & carcinogenesis
Internal medicine
Cohort
Relapsed refractory
medicine
Osteosarcoma
In patient
Lenvatinib
business
Etoposide
medicine.drug
Subjects
Details
- ISSN :
- 15277755 and 0732183X
- Volume :
- 36
- Database :
- OpenAIRE
- Journal :
- Journal of Clinical Oncology
- Accession number :
- edsair.doi...........eb5993bfc3e2fd5fc515ff1f74ccbe51